Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amicus Therapeutics
(NQ:
FOLD
)
11.47
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amicus Therapeutics
< Previous
1
2
Next >
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
August 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 30, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
June 04, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
May 09, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
May 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
March 20, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
March 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
February 15, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
February 08, 2024
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
February 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.
Via
MarketBeat
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
January 07, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
December 05, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
November 08, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
November 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
October 27, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
October 03, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
October 02, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 28, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
September 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 29, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
August 21, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
August 15, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 08, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 31, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
June 27, 2023
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD)
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.